Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2007 August;98(4) > Minerva Medica 2007 August;98(4):385-8

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA MEDICA

A Journal on Internal Medicine


Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236


eTOC

 

EDITORIAL  ENDOSCOPIC ULTRASOUND IN 2007


Minerva Medica 2007 August;98(4):385-8

language: English

Mutations in gastrointestinal stromal tumors diagnosed by endoscopic ultrasound-guided fine needle aspiration

Schmitt F. C. 1, Gomes A. L. 2, Milanezi F. 1,2, Reis R. 2, Bardales R. H. 3

I IPATIMUP and Medical Faculty of Porto University, Porto, Portugal
2 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
3 Outpatient Pathology Associates, Sacramento, California, USA


PDF  


Gastrointestinal stromal tumors (GISTs) are characterized by overexpression and mutations of c-Kit. Approximately 80% of c-Kit mutations occur in exon 11, being a response factor to imatinib (Gleevec) therapy. We aimed to assess whether c-Kit and PDGFRA mutation analysis of GISTs obtained by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) could be routinely performed. Mutation analysis of c-Kit hotspot exons (9, 11, 13 and 17) and PDGFRA hotspot exons (12 and 18) was performed in aspirates 51 mesenchymal tumors. We identified c-Kit mutations in 61% of GIST cases, in accordance with previously published ranges (30-90%). Nearly 95% (19/20) of c-kit-mutant tumors carried exon 11 mutations. Mutation analysis is possible in FNA cell blocks and can assist in the diagnosis and therapeutic decisions in GIST cases.

top of page

Publication History

Cite this article as

Corresponding author e-mail